Physician profile
Alan M Nelson
NPI 1720006117
$5,211.38
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $283 · 2021: $544 · 2022: $808 · 2023: $1,357 · 2024: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.93 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $492.35 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $488.50 | 2019-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $459.48 | 2019-2024 | Entyvio |
| Lilly USA, LLC | $354.22 | 2019-2024 | Omvoh, Mounjaro |
| Pfizer INC. | $329.67 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $216.65 | 2019-2024 | Linzess |
| Genzyme Corporation | $207.17 | 2022-2024 | |
| Qol Medical, LLC | $185.84 | 2019-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $185.46 | 2019-2023 | Dificid |
| Celgene Corporation | $154.40 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $113.90 | 2023 | |
| Amgen INC. | $88.89 | 2021-2024 | Repatha, Otezla |
| Allergan, INC. | $80.01 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $73.21 | 2023-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $71.41 | 2022-2023 | |
| Ardelyx, INC. | $71.34 | 2022-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $69.03 | 2024 | Voquezna |
| Ucb, INC. | $58.58 | 2019 | |
| Fresenius Kabi USA, LLC | $58.28 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $50.33 | 2024 | |
| Organon LLC | $40.98 | 2022-2023 | Hadlima, Renflexis |
| Braintree Laboratories, INC. | $35.87 | 2022-2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $24.17 | 2023 | Dupixent |
| Gilead Sciences, INC. | $23.48 | 2019 | |
| Glaxosmithkline, LLC. | $21.51 | 2023 | Shingrix, Arexvy |
| Redhill Biopharma INC. | $19.30 | 2022 | |
| Daiichi Sankyo INC. | $18.31 | 2019 | |
| Novo Nordisk INC | $18.20 | 2023 | Rybelsus, Ozempic |
| Endo Pharmaceuticals INC. | $15.60 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.